Skip to content
ppharmaranks
Menu
Class IIOngoing

IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial,… recall

FDA recall D-0653-2026 · initiated Jun 10, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 8, 2026How we research

ACCORD BIOPHARMA INC recalled IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… in Jun 2026 — an FDA Class II recall (D-0653-2026) because Lack of assurance of Sterility:.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Lack of assurance of Sterility:

Details

Product
IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Indiana, LLC, 1300 S. Patterson Drive, Bloomington, IN 47403, USA, NDC 69448-019-26.
Recalling company
Accord Biopharma Inc.
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
Jun 10, 2026
FDA report date
Jul 8, 2026

This recall is linked to a product we cover: Imuldosa

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… recalled?
ACCORD BIOPHARMA INC recalled IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… in Jun 2026 — an FDA Class II recall (D-0653-2026) because Lack of assurance of Sterility:. May cause temporary or medically reversible harm; low probability of serious harm.
Why was IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… recalled?
Per the FDA enforcement record, the reason for recall D-0653-2026 was: Lack of assurance of Sterility:
Is a recalled IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single d… are affected?
Distribution: US Nationwide.. The affected lot numbers and expiration dates are listed in the official FDA enforcement record for recall D-0653-2026, initiated Jun 2026.

Source: openFDA Drug Enforcement record D-0653-2026

← All drug recalls